BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34455425)

  • 1. Identification of putative actionable alterations in clinically relevant genes in breast cancer.
    Kaur P; Porras TB; Colombo A; Ring A; Lu J; Kang I; Lang JE
    Br J Cancer; 2021 Oct; 125(9):1270-1284. PubMed ID: 34455425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
    Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
    Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genomic landscape of breast cancer brain metastases: a systematic review.
    Morgan AJ; Giannoudis A; Palmieri C
    Lancet Oncol; 2021 Jan; 22(1):e7-e17. PubMed ID: 33387511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
    Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
    Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
    Curtis C; Shah SP; Chin SF; Turashvili G; Rueda OM; Dunning MJ; Speed D; Lynch AG; Samarajiwa S; Yuan Y; Gräf S; Ha G; Haffari G; Bashashati A; Russell R; McKinney S; ; Langerød A; Green A; Provenzano E; Wishart G; Pinder S; Watson P; Markowetz F; Murphy L; Ellis I; Purushotham A; Børresen-Dale AL; Brenton JD; Tavaré S; Caldas C; Aparicio S
    Nature; 2012 Apr; 486(7403):346-52. PubMed ID: 22522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance of genomic alterations between primary and recurrent breast cancer.
    Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
    Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 9. Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients.
    Ronowicz A; Janaszak-Jasiecka A; Skokowski J; Madanecki P; Bartoszewski R; Bałut M; Seroczyńska B; Kochan K; Bogdan A; Butkus M; Pęksa R; Ratajska M; Kuźniacka A; Wasąg B; Gucwa M; Krzyżanowski M; Jaśkiewicz J; Jankowski Z; Forsberg L; Ochocka JR; Limon J; Crowley MR; Buckley PG; Messiaen L; Dumanski JP; Piotrowski A
    Hum Mutat; 2015 Nov; 36(11):1088-99. PubMed ID: 26219265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine.
    Nagahashi M; Wakai T; Shimada Y; Ichikawa H; Kameyama H; Kobayashi T; Sakata J; Yagi R; Sato N; Kitagawa Y; Uetake H; Yoshida K; Oki E; Kudo SE; Izutsu H; Kodama K; Nakada M; Tse J; Russell M; Heyer J; Powers W; Sun R; Ring JE; Takabe K; Protopopov A; Ling Y; Okuda S; Lyle S
    Genome Med; 2016 Dec; 8(1):136. PubMed ID: 28007036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.
    Baslan T; Kendall J; Volyanskyy K; McNamara K; Cox H; D'Italia S; Ambrosio F; Riggs M; Rodgers L; Leotta A; Song J; Mao Y; Wu J; Shah R; Gularte-Mérida R; Chadalavada K; Nanjangud G; Varadan V; Gordon A; Curtis C; Krasnitz A; Dimitrova N; Harris L; Wigler M; Hicks J
    Elife; 2020 May; 9():. PubMed ID: 32401198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.
    Iyer G; Al-Ahmadie H; Schultz N; Hanrahan AJ; Ostrovnaya I; Balar AV; Kim PH; Lin O; Weinhold N; Sander C; Zabor EC; Janakiraman M; Garcia-Grossman IR; Heguy A; Viale A; Bochner BH; Reuter VE; Bajorin DF; Milowsky MI; Taylor BS; Solit DB
    J Clin Oncol; 2013 Sep; 31(25):3133-40. PubMed ID: 23897969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach.
    Srihari S; Kalimutho M; Lal S; Singla J; Patel D; Simpson PT; Khanna KK; Ragan MA
    Mol Biosyst; 2016 Mar; 12(3):963-72. PubMed ID: 26805938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
    Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
    Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.
    Shen C; Meric-Bernstam F; Su X; Mendelsohn J; Giordano S
    Oncotarget; 2016 Nov; 7(44):71686-71695. PubMed ID: 27634896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
    Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
    Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted mutation detection in breast cancer using MammaSeq™.
    Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
    Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.
    Beca F; Lee SSK; Pareja F; Da Cruz Paula A; Selenica P; Ferrando L; Gularte-Mérida R; Wen HY; Zhang H; Guerini-Rocco E; Rakha EA; Weigelt B; Reis-Filho JS
    Histopathology; 2019 Dec; 75(6):931-937. PubMed ID: 31361912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast Cancer.
    Kaur P; Campo D; Porras TB; Ring A; Lu J; Chairez Y; Su Y; Kang I; Lang JE
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer.
    Ross JS; Gay LM
    Pathology; 2017 Feb; 49(2):120-132. PubMed ID: 28034454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.